Marshall Edwards Inc. - Phenoxodiol

Overview

What is the OVATURE
Trial?

Treatments

Eligibility Criteria

Check Your Eligibility

Cervical Cancer Phase Ib study of Neoadjuvant Use of Oral Phenoxodiol in Patients with Primary Diagnosis of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix, Vagina or Vulva » Read more		NV06-0031

Ovarian Cancer Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous Dosage Form) as a Chemo-Sensitizing Agent for Cisplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer that is Platinum- and/or Taxane-R » Read more		NV06-0037

Ovarian Cancer OVArian TUmor REsponse (OVATURE) Study » Read more		NV06-0039

Ovarian Cancer A randomised placebo-controlled phase Ib/IIa safety, tolerability and efficacy study of oral phenoxodiol in combination with docetaxol versus docetaxol alone in patients with recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer » Read more		Yale 27640

Contact Details

Marshall Edwards, Inc.
140 Wicks Road
North Ryde NSW 2113
Australia

T: +61 2 8877 6196
F: +61 2 9878 8474

email

.	home : about us. : about phenoxodiol : the technology : newsroom : : how to invest : contact details : credits : email Marshall Edwards Inc. 2001 ©